Granulocyte-Macrophage Colony-Stimulating Factor to Harvest Circulating Haemopoietic Stem Cells for Autotransplantation

High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration

“…Only one patient in the present study experienced a microbiologically documented infection (Candida glabrata) and she belonged to the group of patients treated with PBPCs only. The reduction of haematological toxicity in our series and particularly in G-CSF plus EPO-and GM-CSF plus EPO-treated patients translated into a global simplification of the patients' clinical management with a significant reduction of hospital stay compared with several other studies on PBPCT (Gianni et al, 1989;Menichella et al, 1991;Elias et al, 1992;Henon et al, 1992;Sheridan et al, 1992;To et al, 1992;Bensinger et al, 1993;Chao et al, 1993;Peters et al, 1993b;Sica et al, 1993;Pierelli et al, 1994;Shimazaki et al, 1994;Spitzer et al, 1994;Bishop et al, 1994). None of the patients died early of CEM plus PBPCT-related complications and this is one of the best results reported in high-dose treatment with haematopoietic support.…”

“…In terms of non-haematological toxicity, these results are similar to or better than those reported elsewhere for other combinations of high-dose alkylating agents with progenitor cell support in combination or not with etoposide (Williams et al, 1987;Gaspard et al, 1988;Slease et al, 1988;Vincent et al, 1988;Eder et al, 1990;Elias et al, 1991;Williams et al, 1992;Siegert et al, 1994;Benedetti Panici et al, 1995). Our results are better in terms of non-haematological toxicity than those reported recently for patients with high-risk cancer treated with ifosfamide, carboplatin and etoposide (Barnett et al, 1993;Fields et al, 1994;Elias et al, 1995), high-dose cyclophosphamide and etoposide (de Graaf et al, 1994), high-dose cyclophosphamide and carboplatin (Spitzer et al, 1995) , the quality of the graft collected in these patients, most of whom were chemotherapy-naive at the time of PBPC mobilization and collection, made it possible to obtain an accelerated haematopoietic recovery in most patients, faster than that reported in several other experiences of PBPC transplantation (Gianni et al, 1989;Menichella et al, 1991;Elias et al, 1992;To et al, 1992;Henon et al, 1992;Sheridan et al, 1992;Peters et al, 1993b;Sica et al, 1993;Chao et al, 1993;Bensinger et al, 1993;Pierelli et al, 1994;Spitzer et al, 1994;Shimazaki et al, 1994;Bishop et al, 1994). The present study also shows that a significantly faster WBC, PMN and PLT recovery can be achieved by administering G-CSF plus EPO after PBPCT, as described previously (Pierelli et al, 1996).…”

Factors affecting both peripheral blood progenitor cell mobilization and hematopoietic recovery following autologous blood progenitor cell transplantation in multiple myeloma patients: a monocentric study

“…Results obtained in patients with MM 22 and other malignancies 38 showed that following HDCYC the administration of HGF enhanced the number of hematopoietic progenitors harvested. Preliminary results previously reported by our institution have indicated this tendency.…”

CD34+/CD41a+ cells best predict platelet recovery after autologous peripheral blood stem cell transplantation

“…1,2 Chemotherapy and/or hematopoietic growth factors have been used to mobilize stem and progenitor cells into blood for transplantation. [3][4][5][6] However, the minimum number of stem cells for engraftment has not been fully elucidated, and the factors which predict the tempo of hematopoietic recovery are also undefined. Several reports have shown a correlation between the number of colony-forming unit granulocyte-macrophage (CFU-GM) and CD34 + cells Correspondence: Dr C Shimazaki, Second Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kawaramachi-Hirokoji, Kamigyoku, Kyoto, 602, Japan Received 22 November 1997; accepted 27 January 1998 and the time to granulocyte recovery.…”